Watch Out GSK: Vectura And Hikma Target Ellipta Portfolio

08 Nov 2018

• By John Davis

Vectura and Hikma could have generic versions of GSK's Ellipta portfolio ready for marketing when patent protection expires.

The UK-based respiratory specialty company, Vectura Group PLC, which has refocused a significant portion of its research efforts on developing complex inhaled generic products, has entered into an agreement with Hikma Pharmaceuticals PLC on the global development and commercialization of generic versions of GlaxoSmithKline PLC's Ellipta portfolio of respiratory products.

The announcement on Nov. 8 was followed by an 11% increase in Vectura's share price on the London Stock Exchange by the middle of day, as Vectura and Hikma both...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

27 May 2025

• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

27 May 2025

• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

23 May 2025

• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

22 May 2025

• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.